Tactile Systems Technology (NASDAQ:TCMD) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Tactile Systems Technology (NASDAQ:TCMD) issued its quarterly earnings data on Tuesday. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.09, Zacks reports. Tactile Systems Technology had a return on equity of 9.24% and a net margin of 5.42%. Tactile Systems Technology updated its FY 2025 guidance to EPS.

Tactile Systems Technology Trading Up 3.1 %

Shares of NASDAQ:TCMD traded up $0.53 on Tuesday, hitting $17.86. 413,672 shares of the company’s stock were exchanged, compared to its average volume of 247,992. The stock has a market capitalization of $428.64 million, a price-to-earnings ratio of 27.48 and a beta of 1.20. Tactile Systems Technology has a 12 month low of $11.12 and a 12 month high of $21.10. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.37 and a quick ratio of 3.80. The business’s 50 day simple moving average is $17.45 and its two-hundred day simple moving average is $15.61.

Wall Street Analysts Forecast Growth

TCMD has been the topic of several recent research reports. StockNews.com lowered Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 16th. BTIG Research downgraded shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 5th. Finally, Oppenheimer cut shares of Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.